Bioverativ (NASDAQ:BIVV) released its quarterly earnings results on Tuesday. The biotechnology company reported $1.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.73, Bloomberg Earnings reports. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%.
Bioverativ (BIVV) opened at $103.70 on Wednesday. Bioverativ has a fifty-two week low of $43.52 and a fifty-two week high of $104.30.
Several research analysts have weighed in on BIVV shares. Jefferies Group increased their price target on shares of Bioverativ to $79.00 and gave the company a “buy” rating in a report on Thursday, January 18th. Zacks Investment Research raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 target price on the stock in a report on Monday, January 8th. Morgan Stanley raised shares of Bioverativ from an “underweight” rating to an “equal weight” rating in a report on Tuesday, January 23rd. Deutsche Bank set a $53.00 target price on shares of Bioverativ and gave the stock a “hold” rating in a report on Monday, November 20th. Finally, Raymond James Financial cut shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 23rd. Thirteen research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $63.15.
TRADEMARK VIOLATION NOTICE: “Bioverativ (BIVV) Announces Quarterly Earnings Results” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://ledgergazette.com/2018/02/14/bioverativ-bivv-announces-quarterly-earnings-results.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.